Major U.S. Indices Hit All-Time Highs Amid Positive Market Sentiment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CDNA?
Source: seekingalpha
- CareDx Divestiture: CareDx announced the divestment of its Lab Products business to EuroBio Scientific for $170 million in cash, leading to an over 8% surge in after-hours trading, which will allow the company to focus on precision medicine and enhance its competitive edge in the market.
- J.B. Hunt Earnings Beat: J.B. Hunt Transport Services reported a GAAP EPS of $1.49 for the first quarter, surpassing the $1.46 consensus estimate, while operating revenue rose 5% year-over-year to $3.06 billion, indicating strong performance in the logistics sector.
- SL Green Disappoints: SL Green Realty Corp. posted a first-quarter FFO per share of $0.84, missing the $1.08 consensus estimate, although revenue of $253.1 million exceeded expectations, leading to a 4% decline in after-hours trading as the market expressed concerns about future performance.
- QuidelOrtho Revenue Warning: QuidelOrtho issued preliminary first-quarter revenue guidance with a midpoint of $617.5 million, significantly below the $679.59 million consensus, primarily due to a weaker respiratory season and changes in reimbursement policies in China, resulting in an approximately 11% drop in stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 21.420
Low
18.00
Averages
18.00
High
18.00
Current: 21.420
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx Launches AlloSeq Nano Genotyping Solution for Transplant Labs
- Innovative Genotyping Technology: CareDx introduced AlloSeq Nano at the 2026 EFI Conference, a nanopore-based HLA and ABO genotyping solution that delivers high-resolution genotyping in under three hours, significantly enhancing efficiency for transplant laboratories.
- Efficient Workflow: The AlloSeq Nano's single-step amplification and prep workflow requires approximately 45 minutes of hands-on time to assay eleven HLA loci plus ABO in a single test, reducing operational complexity and improving accuracy, thereby enhancing laboratory testing capabilities.
- Product Portfolio Expansion: The launch of AlloSeq Nano expands CareDx's transplant lab products portfolio, supporting a broader range of laboratory throughput requirements and strengthening the company's competitive position in the precision medicine sector.
- Business Restructuring Plan: CareDx announced the divestiture of its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026, allowing the company to focus on its core precision medicine solutions and optimize resource allocation for future growth.
See More
Major U.S. Indices Hit All-Time Highs Amid Positive Market Sentiment
- CareDx Divestiture: CareDx announced the divestment of its Lab Products business to EuroBio Scientific for $170 million in cash, leading to an over 8% surge in after-hours trading, which will allow the company to focus on precision medicine and enhance its competitive edge in the market.
- J.B. Hunt Earnings Beat: J.B. Hunt Transport Services reported a GAAP EPS of $1.49 for the first quarter, surpassing the $1.46 consensus estimate, while operating revenue rose 5% year-over-year to $3.06 billion, indicating strong performance in the logistics sector.
- SL Green Disappoints: SL Green Realty Corp. posted a first-quarter FFO per share of $0.84, missing the $1.08 consensus estimate, although revenue of $253.1 million exceeded expectations, leading to a 4% decline in after-hours trading as the market expressed concerns about future performance.
- QuidelOrtho Revenue Warning: QuidelOrtho issued preliminary first-quarter revenue guidance with a midpoint of $617.5 million, significantly below the $679.59 million consensus, primarily due to a weaker respiratory season and changes in reimbursement policies in China, resulting in an approximately 11% drop in stock price.
See More
CareDx Divests Lab Products Business for $170 Million
- Business Divestiture: CareDx announced the sale of its Lab Products business to EuroBio Scientific for $170 million in cash, aimed at simplifying its operating model and supporting disciplined capital redeployment, with the transaction expected to close by the end of Q3.
- Stock Price Reaction: CareDx shares rose over 8% in after-hours trading, closing at $16.98, reflecting positive market sentiment towards the company's strategic shift and boosting investor confidence.
- Financial Outlook: The company expects first-quarter revenue of approximately $118 million, representing a 39% year-over-year growth, while Wall Street's average estimate stands at $102.49 million, indicating strong growth potential in the precision medicine sector.
- Revenue Breakdown: CareDx anticipates Testing Service revenue to grow by 48% to nearly $91 million, while Lab Products revenue is expected to decline by 4% to about $10 million, indicating a strategic pivot towards more lucrative business areas.
See More
CAREDX INC TO SELL LAB PRODUCTS DIVISION TO EUROBIO SCIENTIFIC FOR $170 MILLION IN CASH
Acquisition Announcement: CareDx has announced its acquisition of Eurobio Scientific's lab products business for $170 million in cash.
Strategic Expansion: This acquisition is part of CareDx's strategy to expand its offerings in the diagnostics and lab products sector.
See More
CareDx Q4 2025 Earnings Call Highlights
- Strong Financial Performance: CareDx reported total revenue of $108.4 million in Q4 2025, a 25% increase year-over-year, with testing services revenue at $78.4 million, indicating sustained growth in the kidney testing sector and enhancing its market competitiveness.
- New Product Launch: The company introduced AlloHeme, an AI-powered surveillance solution for detecting relapse post-allogeneic cell transplantation, which identifies relapse a median of 41 days earlier than clinical detection, with commercial introduction targeted for 2027, expanding the product line and market opportunities.
- Optimistic Outlook: CareDx expects total revenue for 2026 to range between $420 million and $444 million, with testing services projected at $306 million to $326 million, reflecting confidence in future growth despite anticipated negative impacts from the LCD policy.
- Management Changes: Keith Kennedy has been appointed as Chief Operating Officer and Chief Financial Officer, succeeding Nathan Smith, and this management transition may influence the company's strategic execution and financial management, further driving innovation in precision diagnostics.
See More
CareDx (CDNA) Q4 2025 Earnings Call Transcript
See More
CareDx Launches AlloSeq Nano Genotyping Solution for Transplant Labs
- Innovative Genotyping Technology: CareDx introduced AlloSeq Nano at the 2026 EFI Conference, a nanopore-based HLA and ABO genotyping solution that delivers high-resolution genotyping in under three hours, significantly enhancing efficiency for transplant laboratories.
- Efficient Workflow: The AlloSeq Nano's single-step amplification and prep workflow requires approximately 45 minutes of hands-on time to assay eleven HLA loci plus ABO in a single test, reducing operational complexity and improving accuracy, thereby enhancing laboratory testing capabilities.
- Product Portfolio Expansion: The launch of AlloSeq Nano expands CareDx's transplant lab products portfolio, supporting a broader range of laboratory throughput requirements and strengthening the company's competitive position in the precision medicine sector.
- Business Restructuring Plan: CareDx announced the divestiture of its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026, allowing the company to focus on its core precision medicine solutions and optimize resource allocation for future growth.
See More
Major U.S. Indices Hit All-Time Highs Amid Positive Market Sentiment
- CareDx Divestiture: CareDx announced the divestment of its Lab Products business to EuroBio Scientific for $170 million in cash, leading to an over 8% surge in after-hours trading, which will allow the company to focus on precision medicine and enhance its competitive edge in the market.
- J.B. Hunt Earnings Beat: J.B. Hunt Transport Services reported a GAAP EPS of $1.49 for the first quarter, surpassing the $1.46 consensus estimate, while operating revenue rose 5% year-over-year to $3.06 billion, indicating strong performance in the logistics sector.
- SL Green Disappoints: SL Green Realty Corp. posted a first-quarter FFO per share of $0.84, missing the $1.08 consensus estimate, although revenue of $253.1 million exceeded expectations, leading to a 4% decline in after-hours trading as the market expressed concerns about future performance.
- QuidelOrtho Revenue Warning: QuidelOrtho issued preliminary first-quarter revenue guidance with a midpoint of $617.5 million, significantly below the $679.59 million consensus, primarily due to a weaker respiratory season and changes in reimbursement policies in China, resulting in an approximately 11% drop in stock price.
See More
CareDx Divests Lab Products Business for $170 Million
- Business Divestiture: CareDx announced the sale of its Lab Products business to EuroBio Scientific for $170 million in cash, aimed at simplifying its operating model and supporting disciplined capital redeployment, with the transaction expected to close by the end of Q3.
- Stock Price Reaction: CareDx shares rose over 8% in after-hours trading, closing at $16.98, reflecting positive market sentiment towards the company's strategic shift and boosting investor confidence.
- Financial Outlook: The company expects first-quarter revenue of approximately $118 million, representing a 39% year-over-year growth, while Wall Street's average estimate stands at $102.49 million, indicating strong growth potential in the precision medicine sector.
- Revenue Breakdown: CareDx anticipates Testing Service revenue to grow by 48% to nearly $91 million, while Lab Products revenue is expected to decline by 4% to about $10 million, indicating a strategic pivot towards more lucrative business areas.
See More
CAREDX INC TO SELL LAB PRODUCTS DIVISION TO EUROBIO SCIENTIFIC FOR $170 MILLION IN CASH
Acquisition Announcement: CareDx has announced its acquisition of Eurobio Scientific's lab products business for $170 million in cash.
Strategic Expansion: This acquisition is part of CareDx's strategy to expand its offerings in the diagnostics and lab products sector.
See More
CareDx Q4 2025 Earnings Call Highlights
- Strong Financial Performance: CareDx reported total revenue of $108.4 million in Q4 2025, a 25% increase year-over-year, with testing services revenue at $78.4 million, indicating sustained growth in the kidney testing sector and enhancing its market competitiveness.
- New Product Launch: The company introduced AlloHeme, an AI-powered surveillance solution for detecting relapse post-allogeneic cell transplantation, which identifies relapse a median of 41 days earlier than clinical detection, with commercial introduction targeted for 2027, expanding the product line and market opportunities.
- Optimistic Outlook: CareDx expects total revenue for 2026 to range between $420 million and $444 million, with testing services projected at $306 million to $326 million, reflecting confidence in future growth despite anticipated negative impacts from the LCD policy.
- Management Changes: Keith Kennedy has been appointed as Chief Operating Officer and Chief Financial Officer, succeeding Nathan Smith, and this management transition may influence the company's strategic execution and financial management, further driving innovation in precision diagnostics.
See More
CareDx (CDNA) Q4 2025 Earnings Call Transcript
See More
